4,226 reports of this reaction
19.8% of all AXICABTAGENE CILOLEUCEL reports
#1 most reported adverse reaction
CYTOKINE RELEASE SYNDROME is the #1 most commonly reported adverse reaction for AXICABTAGENE CILOLEUCEL, manufactured by Kite Pharma, Inc.. There are 4,226 FDA adverse event reports linking AXICABTAGENE CILOLEUCEL to CYTOKINE RELEASE SYNDROME. This represents approximately 19.8% of all 21,373 adverse event reports for this drug.
Patients taking AXICABTAGENE CILOLEUCEL who experience cytokine release syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOKINE RELEASE SYNDROME is a frequently reported adverse event for AXICABTAGENE CILOLEUCEL, accounting for a significant proportion of all reports.
In addition to cytokine release syndrome, the following adverse reactions have been reported for AXICABTAGENE CILOLEUCEL:
The following drugs have also been linked to cytokine release syndrome in FDA adverse event reports:
CYTOKINE RELEASE SYNDROME has been reported as an adverse event in 4,226 FDA reports for AXICABTAGENE CILOLEUCEL. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOKINE RELEASE SYNDROME accounts for approximately 19.8% of all adverse event reports for AXICABTAGENE CILOLEUCEL, making it one of the most commonly reported side effect.
If you experience cytokine release syndrome while taking AXICABTAGENE CILOLEUCEL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.